Favipiravir treatment in Thai children with COVID-19: effectiveness, safety, and modeling drug exposure
By: Sujittra Chaisavaneeyakorn, Nopporn Apiwattanakul, Chonnamet Techasaensiri, Nattakarn Tantawarak, Bandit Thinkhamrop, Supattra Rungmaitree, Siriporn Phongjitsiri, Tavitiya Sudjaritruk, Suvaporn Anugulruengkitt, Pope Kosalaraksa, Thirapa Nivesvivat, Puttichart Khantee, Pornumpa Bunjoungmanee, Panit Takkinsatian, Thiraporn Kanjanaphan, Rudiwilai Samakoses, Tim R. Cressey, Henry Pertinez, Andrew Owen and Kulkanya Chokephaibulkit
References
- World Health Organization. 2023. WHO COVID-19 dashboard [Internet]. Geneva (CHE): World Health Organization; [cited 2023 Aug 2]. Available from: https://data.who.int/dashboards/covid19/cases?n=c
- World Health Organization. 2023. Clinical characteristics and health outcomes for children hospitalized with COVID-19 [Internet]. Geneva (CHE): World Health Organization; [cited 2023 Aug 2]. Available from: https://www.who.int/publications/i/item/9789240080119
- National Institutes of Health. 2023. COVID-19 treatment guidelines: clinical management of children [Internet]. Bethesda (MD): National Institutes of Health; [cited 2023 Aug 2]. Available from: https://www.covid19treatmentguidelines.nih. gov/management/clinical-management-of-children/nonhospitalized-children-therapeutic-management/
- Agrawal U, Raju R, Udwadia ZF. Favipiravir: a new and emerging antiviral option in COVID-19. Med J Armed Forces India. 2020; 76:370–6. doi: 10.1016/j.mjafi.2020.08.004
- Joshi S, Parkar J, Ansari A, Vora A, Talwar D, Tiwaskar M, et al. Role of favipiravir in the treatment of COVID-19. Int J Infect Dis. 2021; 102:501–8. doi: 10.1016/j.ijid.2020.10.069
- Ministry of Public Health (Thailand), Department of Disease Control. Corona virus disease (COVID-19): guidelines for health care and public health workers [Internet]. (THA): Ministry of Public Health; 2023 [cited 2023 Aug 2]. Available from: https://ddc.moph.go.th/viralpneumonia/eng/guidelines.php
- Ministry of Public Health (Thailand). Details of medicinal product [Internet]. (THA): Ministry of Public Health; 2021 [cited 2023 Aug 2]. Available from: https://pertento.fda.moph.go.th/FDA_SEARCH_DRUG/SEARCH_DRUG/pop-up_drug.aspx?Newcode_U=U1DR1C1012630008611C
- Korula P, Alexander H, John JS, Kirubakaran R, Singh B, Tharyan P, et al. Favipiravir for treating COVID-19. Cochrane Database Syst Rev. 2024; 2:CD015219. doi: 10.1002/14651858.CD015219.pub2
- Sirijatuphat R, Manosuthi W, Niyomnaitham S, Owen A, Copeland KK, Charoenpong L, et al. Early treatment of favipiravir in COVID-19 patients without pneumonia: a multicentre, open-labelled, randomized control study. Emerg Microbes Infect. 2022; 11:2197–206. doi: 10.1080/22221751.2022.2117092
- Siripongboonsitti T, Tawinprai K, Cheirsilpa K, Ungtrakul T, Krisorakun W, Chotipanich C, et al. The real-world clinical outcomes of favipiravir treatment with telemedicine monitoring in preventing disease progression in mild to moderate COVID-19 patients: a retrospective cohort study. Medicina. 2023; 59:1098. doi: 10.3390/medicina59061098
- Polsawat W. Effects of COVID-19 treatment with favipiravir on hospitalized pediatric patients at Kohchan Hospital, Chonburi. J Prapokklao Hosp Clin Med Educat Cent. 2023; 40:1.
- Ministry of Public Health (Thailand), Department of Disease Control. Corona virus disease (COVID-19): guideline for health care workers—treatment guidelines for COVID-19 [Internet]. (THA): Ministry of Public Health; 2020 [cited 2020 Mar 13]. Available from: https://ddc.moph.go.th/viralpneumonia/eng/guidelines.php
- Ministry of Public Health (Thailand), Department of Disease Control. Corona virus disease (COVID-19): guideline for health care workers— guidelines on clinical practice, diagnosis, treatment, and prevention of healthcare-associated infection for COVID-19 [Internet]. (THA): Ministry of Public Health; 2022 [cited 2022 Mar 22]. Available from: https://ddc.moph.go.th/viralpneumonia/eng/guidelines.php
- Aiewsakun P, Jamsai B, Phumiphanjarphak W, Sawaengdee W, Palittapongarnpim P, Mahasirimongkol S. Spatiotemporal evolution of SARS-CoV-2 in the Bangkok metropolitan region, Thailand, 2020–2022: implications for future outbreak preparedness. Microb Genom. 2023; 9:001170. doi: 10.1099/mgen.0.001170
- Sirilak S. Thailand’s experience in the COVID-19 response [Internet]. (THA): Ministry of Public Health; 2020. p. 1–59. Available from: https://ddc.moph.go.th/viralpneumonia/eng/file/pub_doc/LDoc9.pdf
- World Health Organization. COVID-19: symptoms [Internet]. Geneva (CHE): World Health Organization; 2023 [cited 2023 Aug 2]. Available from: https://www.who.int/westernpacific/emergencies/covid-19/information/asymptomatic-covid-19
- World Health Organization. Clinical management of severe acute respiratory infection (SARI) when COVID-19 disease is suspected: interim guidance [Internet]. Geneva (CHE): World Health Organization; 2020 [cited 2023 Aug 2]. Available from: https://www.who.int/publications/i/item/clinical-management-of-covid-19
- Pediatric Acute Lung Injury Consensus Conference Group. Pediatric acute respiratory distress syndrome: consensus recommendations from the pediatric acute lung injury consensus conference. Pediatr Crit Care Med. 2015; 16:428–39. doi: 10.1097/PCC.0000000000000350
- Rajpurkar M, Lusher J. Clinical and laboratory approach to the patient with bleeding. In: Nathan DG, Orkin SH, Ginsburg D, Look AT, editors. Nathan and Oski’s hematology of infancy and childhood. 7th ed. Philadelphia: WB Saunders; 2009, p. 1449–:61.
- Prasanchaimontri IO, Manosuthi W, Pertinez H, Owen A, Niyomnaitham S, Sirijatuphat R, et al. Favipiravir pharmacokinetics in Thai adults with mild COVID-19: a sub-study of interpatient variability and ethnic differences in exposure. Pharmacol Res Perspect. 2024; 12:e1233. doi: 10.1002/prp2.1233
- Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol. 2008; 48:303–32. doi: 10.1146/annurev.pharmtox.48.113006.094708
- R Core Team. R: a language and environment for statistical computing [Internet]. Vienna (AUT): R Foundation for Statistical Computing; 2020 [cited 2023 Aug 2]. Available from: https://www.R-project.org/.
- Wang M, Cao R, Zhang L, Yang X, Liu J, Xu M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020; 30:269–71. doi: 10.1038/s41422-020-0282-0
- Kaptein SJF, Jacobs S, Langendries L, Seldeslachts L, Ter Horst S, Liesenborghs L, et al. Favipiravir at high doses has potent antiviral activity in SARS-CoV-2-infected hamsters, whereas hydroxychloroquine lacks activity. Proc Natl Acad Sci U S A. 2020; 117:26955–65. doi: 10.1073/pnas.2014441117
- Fujii S, Ibe Y, Ishigo T, Inamura H, Kunimoto Y, Fujiya Y, et al. Early favipiravir treatment was associated with early defervescence in non-severe COVID-19 patients. J Infect Chemother. 2021; 27:1051–7. doi: 10.1016/j.jiac.2021.04.013
- Doi Y, Hibino M, Hase R, Yamamoto M, Kasamatsu Y, Hirose M, et al. A prospective, randomized, open-label trial of early versus late favipiravir therapy in hospitalized patients with COVID-19. Antimicrob Agents Chemother. 2020; 64:e01897–20. doi: 10.1128/AAC.01897-20
- Hassanipour S, Arab-Zozani M, Amani B, Heidarzad F, Fathalipour M, Martinez-de-Hoyo R. The efficacy and safety of favipiravir in treatment of COVID-19: a systematic review and meta-analysis of clinical trials. Sci Rep. 2021; 11:11022. doi: 10.1038/s41598-021-90551-6
- Manabe T, Kambayashi D, Akatsu H, Kudo K. Favipiravir for the treatment of patients with COVID-19: a systematic review and meta-analysis. BMC Infect Dis. 2021; 21:489. doi: 10.1186/s12879-021-06164-x
- Deng W, Yang C, Yang S, Chen H, Qiu Z, Chen J. Evaluation of favipiravir in the treatment of COVID-19 based on the real world. Expert Rev Anti Infect Ther. 2022; 20:555–65. doi: 10.1080/14787210.2022.2012155
- Srisubat A, Thanasitthichai S, Kongsaengdao S, Maneeton N, Maneeton B, Akksilp S. Effectiveness of favipiravir monotherapy in the treatment of COVID-19: real world data analysis from Thailand. Lancet Reg Health Southeast Asia. 2023; 11:100166. doi: 10.1016/j.lansea.2023.100166
- Golan Y, Campos JAS, Woolson R, Cilla D, Hanabergh R, Gonzales-Rojas Y, et al. Favipiravir in patients with early mild-to-moderate coronavirus disease 2019 (COVID-19): a randomized controlled trial. Clin Infect Dis. 2023; 76:e10–7. doi: 10.1093/cid/ciac712
- Bosaeed M, Alharbi A, Mahmoud E, Alrehily S, Bahlaq M, Gaifer Z, et al. Efficacy of favipiravir in adults with mild COVID-19: a randomized, double-blind, multicentre, placebo-controlled clinical trial. Clin Microbiol Infect. 2022; 28:602–8. doi: 10.1016/j. cmi.2021.12.026
- Vaezi A, Salmasi M, Soltaninejad F, Salahi M, Javanmard SH, Amra B. Favipiravir in the treatment of outpatient COVID-19: a multicenter, randomized, triple-blind, placebo-controlled clinical trial. Adv Respir Med. 2023; 91:18–25. doi: 10.3390/arm91010004
- Udwadia ZF, Singh P, Barkate H, Patil S, Rangwala S, Pendse A, et al. Efficacy and safety of favipiravir, an oral RNA-dependent RNA polymerase inhibitor, in mild-to-moderate COVID-19: a randomized, comparative, open-label, multicenter, phase 3 clinical trial. Int J Infect Dis. 2021; 103:62–71. doi: 10.1016/j.ijid.2020.11.142
- Kamali A, Sarmadian H, Mahmoodiyeh B, Valibeik S, Farmani F, Bashirgonbadi Z. Evaluation of the effect of favipiravir on patients with COVID-19. J Family Med Prim Care. 2023; 12:242–5. doi: 10.4103/jfmpc.jfmpc_1058_22
- Shah PL, Orton CM, Grinsztejn B, Donaldson GC, Crabtree Ramírez B, Tonkin J, et al. Favipiravir in patients hospitalised with COVID-19 (PIONEER trial): a multicentre, open-label, phase 3, randomised controlled trial of early intervention versus standard care. Lancet Respir Med. 2023; 11:415–24. doi: 10.1016/S2213-2600(22)00412-X
- Doi Y, Ishihara T, Banno S, Ando M, Kondo M. Favipiravir observational study. Favipiravir for symptomatic COVID-19: a nationwide observational cohort study. J Infect Chemother. 2023; 29:150–6. doi: 10.1016/j.jiac.2022.10.008
- Anugulruengkitt S, Teeraananchai S, Chantasrisawad N, Promsena P, Jantarabenjakul W, Puthanakit T. Clinical outcomes of pediatric COVID-19 in a tertiary care center in Bangkok, Thailand. IJID Reg. 2021; 1:159–62. doi: 10.1016/j.ijregi.2021.11.003
- Ozsurekci Y, Oygar PD, Gürlevik SL, Kesici S, Ozen S, Kurt Sukur ED, et al. Favipiravir use in children with COVID-19 and acute kidney injury: is it safe? Pediatr Nephrol. 2021; 36:3771–6. doi: 10.1007/s00467-021-05111-x
Language: English
Page range: 96 - 113
Published on: Apr 30, 2026
Published by: Chulalongkorn University
In partnership with: Paradigm Publishing Services
Publication frequency: 6 issues per year
Keywords:
Related subjects:
© 2026 Sujittra Chaisavaneeyakorn, Nopporn Apiwattanakul, Chonnamet Techasaensiri, Nattakarn Tantawarak, Bandit Thinkhamrop, Supattra Rungmaitree, Siriporn Phongjitsiri, Tavitiya Sudjaritruk, Suvaporn Anugulruengkitt, Pope Kosalaraksa, Thirapa Nivesvivat, Puttichart Khantee, Pornumpa Bunjoungmanee, Panit Takkinsatian, Thiraporn Kanjanaphan, Rudiwilai Samakoses, Tim R. Cressey, Henry Pertinez, Andrew Owen, Kulkanya Chokephaibulkit, published by Chulalongkorn University
This work is licensed under the Creative Commons Attribution 4.0 License.